PPD Opens Office in Novosibirsk, Russia

PPD Opens Office in Novosibirsk, Russia
Expands company's already strong presence in Eastern Europe
 

WILMINGTON, N.C., Sep 30, 2010 (BUSINESS WIRE) -- PPD, Inc. /quotes/comstock/15*!ppdi/quotes/nls/ppdi (PPDI 24.94, +0.15, +0.61%) today announced it has opened an office in Novosibirsk, Russia, building on the growth of its Phase II-IV clinical development services in Eastern Europe. PPD will provide clinical monitoring services in key therapeutic areas from this location.

The new office strengthens PPD's presence in Russia, a country where it already has offices in Moscow, Smolensk and St. Petersburg. PPD is one of the largest CROs operating in Central and Eastern Europe, an important, high-growth market for clinical trials that offers efficient access to patients and a well-developed, centralized health care system.

"Establishing a presence in Novosibirsk allows us to serve clients more effectively and keep pace with clinical trial growth in this region," said Roger Newbery, vice president of clinical development for Europe, Middle East and Africa. "This expansion provides us the ability to reach more than five million people and grow our number of investigator sites to meet growing client demand."

The office is located at 2 Dimitrova Prospect, Novosibirsk 630099, Russia. For more information about PPD services provided from the Novosibirsk office, call +44 1223 374430.

PPD is a leading global contract research organization, celebrating 25 years of providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 42 countries and more than 10,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.